[{"id":"2f9874c4-f677-4e33-b8c8-e0765095f8b3","acronym":"DUAL-OV-CAR-NK","url":"https://clinicaltrials.gov/study/NCT07480954","created_at":"2026-03-28T01:39:31.330Z","updated_at":"2026-03-28T01:39:31.330Z","phase":"Phase 1/2","brief_title":"Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)","source_id_and_acronym":"NCT07480954 - DUAL-OV-CAR-NK","lead_sponsor":"Beijing Biotech","biomarkers":" FOLR1 • MSLN • MUC16","pipe":"","alterations":" ","tags":["FOLR1 • MSLN • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 02/04/2026","start_date":" 02/04/2026","primary_txt":" Primary completion: 02/17/2027","primary_completion_date":" 02/17/2027","study_txt":" Completion: 05/17/2028","study_completion_date":" 05/17/2028","last_update_posted":"2026-03-18"},{"id":"8100f49e-ecbc-41b2-9130-5ed625da8fc7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04669496","created_at":"2025-02-25T13:40:17.235Z","updated_at":"2025-02-25T13:40:17.235Z","phase":"Phase 2/3","brief_title":"Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma with High-risk Recurrence Factors","source_id_and_acronym":"NCT04669496","lead_sponsor":"Shanghai Zhongshan Hospital","biomarkers":" TMB • MSI • CEACAM5 • MUC16","pipe":" | ","alterations":" PD-L1 expression","tags":["TMB • MSI • CEACAM5 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lenvima (lenvatinib) • Loqtorzi (toripalimab-tpzi) • oxaliplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 178","initiation":"Initiation: 01/20/2021","start_date":" 01/20/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-21"},{"id":"8061a0a4-90b7-438d-bd01-079e025dc238","acronym":"","url":"https://clinicaltrials.gov/study/NCT03113487","created_at":"2021-01-18T15:20:26.946Z","updated_at":"2025-02-25T14:01:16.153Z","phase":"Phase 2","brief_title":"P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","source_id_and_acronym":"NCT03113487","lead_sponsor":"City of Hope Medical Center","biomarkers":" PD-L1 • TP53 • MUC16","pipe":" | ","alterations":" TP53 mutation","tags":["PD-L1 • TP53 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • p53MVA"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 02/01/2018","start_date":" 02/01/2018","primary_txt":" Primary completion: 08/26/2022","primary_completion_date":" 08/26/2022","study_txt":" Completion: 06/03/2025","study_completion_date":" 06/03/2025","last_update_posted":"2025-02-19"},{"id":"56170b22-f9c8-453b-b976-39bba6ed5d1e","acronym":"CIP2023-001","url":"https://clinicaltrials.gov/study/NCT06366490","created_at":"2024-04-16T20:48:26.282Z","updated_at":"2025-02-25T14:18:59.745Z","phase":"Phase 1","brief_title":"Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy in Recurrent Epithelial Ovarian Cancer","source_id_and_acronym":"NCT06366490 - CIP2023-001","lead_sponsor":"PhotonPharma, Inc.","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 06/30/2025","start_date":" 06/30/2025","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-17"},{"id":"d94f7980-52bd-4422-b97d-6ffc7470ef49","acronym":"NRG-GY031","url":"https://clinicaltrials.gov/study/NCT05950464","created_at":"2023-07-20T15:09:28.523Z","updated_at":"2025-02-25T14:42:14.385Z","phase":"Phase 1","brief_title":"Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer","source_id_and_acronym":"NCT05950464 - NRG-GY031","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PIK3CA • MSI • MYC • ARID1A • MUC16 • HEXIM1","pipe":" | ","alterations":" MSI-H/dMMR","tags":["PIK3CA • MSI • MYC • ARID1A • MUC16 • HEXIM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ZEN-3694 • tuvusertib (M1774)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 12/18/2023","start_date":" 12/18/2023","primary_txt":" Primary completion: 04/30/2026","primary_completion_date":" 04/30/2026","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2025-02-14"},{"id":"e2d37db5-45cf-4e65-9db8-5800eea57b12","acronym":"HIPEC","url":"https://clinicaltrials.gov/study/NCT04415944","created_at":"2021-01-18T21:17:02.131Z","updated_at":"2025-02-25T15:18:39.353Z","phase":"Phase 2","brief_title":"Trial Evaluating Feasibility and Quality of Life of Second Look Laparoscopy With Hyperthermic Intraperitoneal Chemotherapy","source_id_and_acronym":"NCT04415944 - HIPEC","lead_sponsor":"Wake Forest University Health Sciences","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 05/20/2021","start_date":" 05/20/2021","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2025-02-12"},{"id":"80fa2f9c-498f-458f-b650-2771cce8af16","acronym":"","url":"https://clinicaltrials.gov/study/NCT05952453","created_at":"2023-07-20T14:08:52.311Z","updated_at":"2025-02-25T15:28:12.738Z","phase":"Phase 2","brief_title":"Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro","source_id_and_acronym":"NCT05952453","lead_sponsor":"University of Alabama at Birmingham","biomarkers":" CEACAM5 • MUC16","pipe":"","alterations":" ","tags":["CEACAM5 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • carboplatin • paclitaxel"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 02/28/2025","start_date":" 02/28/2025","primary_txt":" Primary completion: 10/30/2028","primary_completion_date":" 10/30/2028","study_txt":" Completion: 12/30/2030","study_completion_date":" 12/30/2030","last_update_posted":"2025-02-10"},{"id":"cad13ffd-6e59-4a47-a0dc-e14e5025dcde","acronym":"","url":"https://clinicaltrials.gov/study/NCT02884648","created_at":"2021-01-18T14:09:35.489Z","updated_at":"2025-02-25T16:30:59.280Z","phase":"Phase 2","brief_title":"Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery","source_id_and_acronym":"NCT02884648","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 11/15/2016","start_date":" 11/15/2016","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2025-02-07"},{"id":"d44eaa90-9658-4ecd-acb1-1e96d85b2993","acronym":"FRAPPE","url":"https://clinicaltrials.gov/study/NCT05920798","created_at":"2023-06-27T14:08:13.033Z","updated_at":"2025-02-25T16:33:33.170Z","phase":"Phase 1/2","brief_title":"Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer","source_id_and_acronym":"NCT05920798 - FRAPPE","lead_sponsor":"Mayo Clinic","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 09/28/2023","start_date":" 09/28/2023","primary_txt":" Primary completion: 07/15/2027","primary_completion_date":" 07/15/2027","study_txt":" Completion: 07/15/2027","study_completion_date":" 07/15/2027","last_update_posted":"2025-02-07"},{"id":"75e429d1-288b-438c-890d-57227288a551","acronym":"","url":"https://clinicaltrials.gov/study/NCT00436254","created_at":"2021-01-18T01:32:21.652Z","updated_at":"2025-02-25T16:35:57.454Z","phase":"Phase 1","brief_title":"Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer","source_id_and_acronym":"NCT00436254","lead_sponsor":"University of Washington","biomarkers":" HER-2 • MUC16","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification","tags":["HER-2 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AST-301 • Leukine (sargramostim)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 10/01/2001","start_date":" 10/01/2001","primary_txt":" Primary completion: 03/01/2010","primary_completion_date":" 03/01/2010","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2025-02-06"},{"id":"074f4f72-e179-49af-b9d4-a6b1faee4ca3","acronym":"NRG-GY021","url":"https://clinicaltrials.gov/study/NCT04034927","created_at":"2021-01-18T19:48:04.192Z","updated_at":"2025-02-25T17:00:08.274Z","phase":"Phase 2","brief_title":"Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer","source_id_and_acronym":"NCT04034927 - NRG-GY021","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • BRCA • MUC16","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2 • BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imjudo (tremelimumab-actl)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 61","initiation":"Initiation: 12/04/2019","start_date":" 12/04/2019","primary_txt":" Primary completion: 07/31/2021","primary_completion_date":" 07/31/2021","study_txt":" Completion: 09/18/2025","study_completion_date":" 09/18/2025","last_update_posted":"2025-02-03"},{"id":"b72b0a64-54a8-4a42-8b82-b948a538ae47","acronym":"CAPRI","url":"https://clinicaltrials.gov/study/NCT03462342","created_at":"2021-01-18T17:04:00.829Z","updated_at":"2025-02-25T14:58:45.950Z","phase":"Phase 2","brief_title":"Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer","source_id_and_acronym":"NCT03462342 - CAPRI","lead_sponsor":"University of Pennsylvania","biomarkers":" HRD • BRCA • MUC16","pipe":" | ","alterations":" HRD • BRCA mutation","tags":["HRD • BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • ceralasertib (AZD6738)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 03/09/2018","start_date":" 03/09/2018","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-01-31"},{"id":"e92801f2-3769-4416-bd81-1192ec053342","acronym":"","url":"https://clinicaltrials.gov/study/NCT02754726","created_at":"2021-01-18T13:30:16.481Z","updated_at":"2025-02-25T14:36:19.669Z","phase":"Phase 2","brief_title":"Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma","source_id_and_acronym":"NCT02754726","lead_sponsor":"HonorHealth Research Institute","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cisplatin • gemcitabine • albumin-bound paclitaxel"],"overall_status":"Completed","enrollment":" Enrollment 35","initiation":"Initiation: 04/01/2016","start_date":" 04/01/2016","primary_txt":" Primary completion: 04/11/2023","primary_completion_date":" 04/11/2023","study_txt":" Completion: 03/22/2024","study_completion_date":" 03/22/2024","last_update_posted":"2024-12-10"},{"id":"9dd1dfec-0aa4-4556-89c3-d62638f6b981","acronym":"","url":"https://clinicaltrials.gov/study/NCT03761914","created_at":"2021-01-18T18:29:09.264Z","updated_at":"2025-02-25T16:08:40.101Z","phase":"Phase 1/2","brief_title":"Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers","source_id_and_acronym":"NCT03761914","lead_sponsor":"Sellas Life Sciences Group","biomarkers":" HER-2 • KRAS • PGR • WT1 • BRCA • MUC16","pipe":" | ","alterations":" HER-2 negative • KRAS wild-type • RAS wild-type • BRCA mutation","tags":["HER-2 • KRAS • PGR • WT1 • BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • KRAS wild-type • RAS wild-type • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • oxaliplatin • irinotecan • Zeltherva (galinpepimut-S) • hydroxyurea • Leukine (sargramostim)"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 09/30/2019","start_date":" 09/30/2019","primary_txt":" Primary completion: 07/05/2022","primary_completion_date":" 07/05/2022","study_txt":" Completion: 10/27/2022","study_completion_date":" 10/27/2022","last_update_posted":"2024-11-19"},{"id":"11e75b19-80f9-40c8-bd95-a1ed86eb8fbe","acronym":"MY-IOTA","url":"https://clinicaltrials.gov/study/NCT06693596","created_at":"2025-02-26T13:54:59.591Z","updated_at":"2025-02-26T13:54:59.591Z","phase":"","brief_title":"Masses in Young Patients - International Ovarian Tumour Analysis (MY-IOTA)","source_id_and_acronym":"NCT06693596 - MY-IOTA","lead_sponsor":"Universitaire Ziekenhuizen KU Leuven","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"],"overall_status":"Recruiting","enrollment":" Enrollment 1000","initiation":"Initiation: 11/20/2024","start_date":" 11/20/2024","primary_txt":" Primary completion: 07/21/2026","primary_completion_date":" 07/21/2026","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2024-11-18"},{"id":"4f33daa7-3ce5-4186-b28f-85f4758b6b4b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01116648","created_at":"2021-01-18T04:25:31.641Z","updated_at":"2025-02-25T16:23:24.150Z","phase":"Phase 1/2","brief_title":"Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer","source_id_and_acronym":"NCT01116648","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA • MUC16","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Recentin (cediranib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 155","initiation":"Initiation: 04/14/2010","start_date":" 04/14/2010","primary_txt":" Primary completion: 10/31/2018","primary_completion_date":" 10/31/2018","study_txt":" Completion: 02/13/2025","study_completion_date":" 02/13/2025","last_update_posted":"2024-10-31"},{"id":"a32ecad7-5454-46b4-8444-9e5355b8f01d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03162627","created_at":"2021-01-18T15:35:40.609Z","updated_at":"2025-02-25T14:58:06.370Z","phase":"Phase 1","brief_title":"Selumetinib and Olaparib in Solid Tumors","source_id_and_acronym":"NCT03162627","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" KRAS • BRAF • HRAS • NF1 • MUC16","pipe":"","alterations":" ","tags":["KRAS • BRAF • HRAS • NF1 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Koselugo (selumetinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 08/04/2017","start_date":" 08/04/2017","primary_txt":" Primary completion: 08/30/2026","primary_completion_date":" 08/30/2026","study_txt":" Completion: 08/30/2026","study_completion_date":" 08/30/2026","last_update_posted":"2024-10-16"},{"id":"57e9cf07-fbd3-4b60-b000-b857b664ab20","acronym":"ATARI","url":"https://clinicaltrials.gov/study/NCT04065269","created_at":"2021-01-18T19:55:05.811Z","updated_at":"2025-02-25T15:08:44.072Z","phase":"Phase 2","brief_title":"ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss","source_id_and_acronym":"NCT04065269 - ATARI","lead_sponsor":"Institute of Cancer Research, United Kingdom","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • ceralasertib (AZD6738)"],"overall_status":"Recruiting","enrollment":" Enrollment 174","initiation":"Initiation: 11/27/2019","start_date":" 11/27/2019","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2024-07-11"},{"id":"547414d8-facd-47ac-bdb8-a247edecacd3","acronym":"","url":"https://clinicaltrials.gov/study/NCT00043472","created_at":"2021-01-18T00:03:35.293Z","updated_at":"2024-07-02T16:34:25.754Z","phase":"","brief_title":"Removal of the Ovaries/Fallopian Tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk","source_id_and_acronym":"NCT00043472","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • MUC16","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 07/09/2003","start_date":" 07/09/2003","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2024-06-14"},{"id":"023cf6d7-38d4-4089-89bb-ebee230e66e8","acronym":"GLORIOSA","url":"https://clinicaltrials.gov/study/NCT05445778","created_at":"2022-07-06T15:54:42.215Z","updated_at":"2024-07-02T16:34:26.631Z","phase":"Phase 3","brief_title":"Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA)","source_id_and_acronym":"NCT05445778 - GLORIOSA","lead_sponsor":"ImmunoGen, Inc.","biomarkers":" FOLR1 • BRCA • MUC16","pipe":" | ","alterations":" FOLR1 expression • MUC16 elevation","tags":["FOLR1 • BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLR1 expression • MUC16 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Elahere (mirvetuximab soravtansine-gynx)"],"overall_status":"Recruiting","enrollment":" Enrollment 418","initiation":"Initiation: 12/27/2022","start_date":" 12/27/2022","primary_txt":" Primary completion: 03/01/2027","primary_completion_date":" 03/01/2027","study_txt":" Completion: 04/01/2029","study_completion_date":" 04/01/2029","last_update_posted":"2024-06-13"},{"id":"413409a2-0792-4de1-a64e-d4d1801140e0","acronym":"","url":"https://clinicaltrials.gov/study/NCT03586661","created_at":"2021-01-18T17:38:28.376Z","updated_at":"2024-07-02T16:34:27.534Z","phase":"Phase 1","brief_title":"Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","source_id_and_acronym":"NCT03586661","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRCA • MUC16","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • Aliqopa (copanlisib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 04/29/2019","start_date":" 04/29/2019","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-06-11"},{"id":"6e1dbdb2-1155-441b-82fa-55d2afdded14","acronym":"","url":"https://clinicaltrials.gov/study/NCT03759587","created_at":"2021-01-18T18:28:41.870Z","updated_at":"2024-07-02T16:34:37.340Z","phase":"Phase 2","brief_title":"Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer","source_id_and_acronym":"NCT03759587","lead_sponsor":"Takeda","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Zejula (niraparib)"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 12/28/2018","start_date":" 12/28/2018","primary_txt":" Primary completion: 03/17/2019","primary_completion_date":" 03/17/2019","study_txt":" Completion: 12/28/2022","study_completion_date":" 12/28/2022","last_update_posted":"2024-06-07"},{"id":"52cbeb93-cca2-4926-a33c-663060dd271d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06083844","created_at":"2023-10-16T16:13:46.644Z","updated_at":"2024-07-02T16:35:00.052Z","phase":"Phase 2","brief_title":"Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy","source_id_and_acronym":"NCT06083844","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRCA1 • BRCA2 • MUC16","pipe":" | ","alterations":" MUC16 elevation","tags":["BRCA1 • BRCA2 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC16 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Avastin (bevacizumab) • cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 12/12/2023","start_date":" 12/12/2023","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2024-05-30"},{"id":"84572fdb-bb5f-45fd-aa5f-f18dedb5e9a6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05334069","created_at":"2022-04-19T23:53:56.743Z","updated_at":"2024-07-02T16:35:01.625Z","phase":"","brief_title":"Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection","source_id_and_acronym":"NCT05334069","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" MUC16","pipe":" | ","alterations":" MUC16 elevation","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC16 elevation"],"overall_status":"Recruiting","enrollment":" Enrollment 2000","initiation":"Initiation: 08/01/2022","start_date":" 08/01/2022","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-05-23"}]